Home » The Importance of Prostate-Specific Membrane Antigen in Prostate Cancer

The Importance of Prostate-Specific Membrane Antigen in Prostate Cancer

by Andrew Jonathan

Prostate-specific membrane antigen (PSMA) is an integral part of the human prostate. Studies have consistently demonstrate PSMA expression in all types of prostate tissue and increase PSMA expression in cancer tissue. Suggesting that PSMA could play an important role in cancerous progression [1]. In fact, as early as 1995. Scientists were suggesting that targeting PSMA with new drugs could be useful in treating prostate cancer [2]. Fortunately, more recent research has valid these findings and suggests that PSMA might play an even more significant role than previously thought in the development of prostate cancer

What Is Prostate Specific Membrane Antigen?

Prostate-specific membrane antigen (PSMA) is a small glycoprotein that binds to the cell membrane of prostate epithelial cells. Studies have consistently demonstrate PSMA expression in all types of prostate tissue and increase PSMA expression in cancer tissue. One way this can be observe is through immunohistochemistry on prostate tumor samples. Which shows that the cytoplasmic regions often show reactivity. Because of the lack of clarity regarding how PSMA functions, scientists and researchers have been debating this issue frequently. why some cells are disproportionately more sensitive to their presence than others.

What Do We Know About PSMA?

PSMA is an oncogene that triggers prostate cancer tumor progression. It is important to understand how PSMA works. Especially as a test for early detection. PSMA can be detect through the use of immunohistochemistry to visualize the staining with a peroxidase and diaminobenzidine protocol or with magnetic resonance imaging. As PSMA is express all types of prostate tissue. It has been shown to be a better biomarker than PSA. Studies have demonstrate that as there are higher levels of PSMA expression. Tumor progression will also increase, leading to metastatic disease at higher rates

What Are the Benefits of Targeting Its Expression?

In the past, many physicians interpret PSMA positivity as a sign that the cancer was growing or spreading outside the prostate gland. However, this assumption may not be accurate because some cancers are able to metastasize before they express PSMA. Instead, targeting its expression may help surgeons more accurately assess which tumors need surgery. Furthermore, after PSMA is target with monoclonal antibodies it could be use to track disease progression and treatment effectiveness.

Studies have shown that combine with radiolabeled anti-PSMA receptor proteins can result in excellent tumor uptake and emission imaging with minimal exposure to radiation compare to conventional radiolabeling procedures.

How Can We Target PSMA?

PSMA has an integral role in the progression and development of prostate cancer. As such, there are multiple ways that this biomarker can be target for therapeutic purposes. expression can be decrease by inhibiting factors that increase its production and increasing the expression of regulatory proteins that downregulate it. There is a polypeptide with high affinity for PSMA. Which when conjugated to antibodies or other agents. Provides increase specificity and a more effective therapy due to increase penetration of cells. This method has demonstrate successful outcomes at low doses and minimizes potential side effects on surrounding tissue as seen with traditional cytotoxic chemotherapy drugs

Anti-PSMA Antibodies

Prostate cancer patients with advance metastatic prostate cancer as well as some patients with localize and organ-confine prostate cancer are candidates for anti-PSMA antibodies therapy. Anti-PSMA antibodies can be use to target the PSMA antigen. Which is highly express in prostate tumors and provides a tumor immunogenic signature. This signature can be detect by immune cells, identify, and eliminate. Combining the efficacy and safety of these therapies has great potential to improve outcomes for the group of men that do not respond to conventional treatments

Clinical Evaluation of PSMA

Base on the current findings, there appears to be a high association of PSMA expression with prostate cancer. We also found that while the majority of normal tissues express PSMA, it is an oncogenic and luminal antigen not typically found in metastatic disease. The specificity and sensitivity detect by our study warrant further exploration as to PS MA’s role as a potential biomarker for prostate cancer.

Diagnostic Applications

PSMA expression is assesses by immunohistochemistry or by fluorescence microscopy. The sensitivity and specificity to predict prostate cancer vary depending on the type of study and diagnostic tool use. Overall, PSMA is consider a useful marker for differential diagnosis because it predicts tumor grade and recurrence after surgery with a high degree of accuracy. But PSMA does not always discriminate well between benign prostatic hyperplasia (BPH) and cancer. This can be explain by the overlap between non-neoplastic prostate glandular epithelium and neoplastic glandular epithelium in both normal prostate tissue adjacent to tumors as well as adjacent BPH  

Therapeutic Interventions

There are some practical implications of PSMA-target therapies. For example, anti-PSMA therapy can be consider as a diagnostic tool to distinguish prostate cancer from benign prostatic hyperplasia or inflammation. Additionally, evidence suggests that immunotherapy may be able to induce antibody responses against other antigens express by the tumor cells. These factors may provide an opportunity for early detection and treatment of prostate cancer without the side effects that come with radiation and hormone treatments.

Related Posts

Marketmillion logo

MarketMillion is an online webpage that provides business news, tech, telecom, digital marketing, auto news, and website reviews around World.

Contact us: [email protected]

@2022 – MarketMillion. All Right Reserved. Designed by Techager Team